204 related articles for article (PubMed ID: 20188205)
1. Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats.
Kuang T; Wang J; Pang B; Huang X; Burg ED; Yuan JX; Wang C
Pulm Pharmacol Ther; 2010 Oct; 23(5):456-64. PubMed ID: 20188205
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats.
Sawamura F; Kato M; Fujita K; Nakazawa T; Beardsworth A
J Pharmacol Sci; 2009 Nov; 111(3):235-43. PubMed ID: 19881228
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats.
Elias-Al-Mamun M; Satoh K; Tanaka S; Shimizu T; Nergui S; Miyata S; Fukumoto Y; Shimokawa H
Circ J; 2014; 78(4):967-76. PubMed ID: 24553194
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin and sildenafil combine to attenuate pulmonary hypertension.
Zhao L; Sebkhi A; Ali O; Wojciak-Stothard B; Mamanova L; Yang Q; Wharton J; Wilkins MR
Eur Respir J; 2009 Oct; 34(4):948-57. PubMed ID: 19797670
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.
Xie YP; Chen B; Sanders P; Guo A; Li Y; Zimmerman K; Wang LC; Weiss RM; Grumbach IM; Anderson ME; Song LS
Hypertension; 2012 Feb; 59(2):355-62. PubMed ID: 22203744
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effects of 2-methoxyestradiol with either sildenafil or bosentan on amelioration of monocrotaline-induced pulmonary hypertension and vascular remodeling.
Tofovic SP; Jones TJ; Bilan VP; Jackson EK; Petrusevska G
J Cardiovasc Pharmacol; 2010 Nov; 56(5):475-83. PubMed ID: 20881615
[TBL] [Abstract][Full Text] [Related]
7. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary hemodynamic response to acute combination and monotherapy with sildenafil and brain natriuretic peptide in rats with monocrotaline-induced pulmonary hypertension.
Carlino C; Tobias JD; Schneider RI; Heller RL; Alpert MA; Grueber RE; Dellsperger KC; Demarco VG
Am J Med Sci; 2010 Jan; 339(1):55-9. PubMed ID: 19996941
[TBL] [Abstract][Full Text] [Related]
9. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.
Clozel M; Hess P; Rey M; Iglarz M; Binkert C; Qiu C
Exp Biol Med (Maywood); 2006 Jun; 231(6):967-73. PubMed ID: 16741032
[TBL] [Abstract][Full Text] [Related]
10. The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: a hemodynamic and biochemical study.
Jasińska-Stroschein M; Owczarek J; Łuczak A; Orszulak-Michalak D
Pharmacology; 2013; 91(3-4):178-84. PubMed ID: 23428587
[TBL] [Abstract][Full Text] [Related]
11. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of SOC/Ca2+/NFAT pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells.
Wang C; Li JF; Zhao L; Liu J; Wan J; Wang YX; Wang J; Wang C
Respir Res; 2009 Dec; 10(1):123. PubMed ID: 20003325
[TBL] [Abstract][Full Text] [Related]
13. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Mouchaers KT; Schalij I; de Boer MA; Postmus PE; van Hinsbergh VW; van Nieuw Amerongen GP; Vonk Noordegraaf A; van der Laarse WJ
Eur Respir J; 2010 Oct; 36(4):800-7. PubMed ID: 20351034
[TBL] [Abstract][Full Text] [Related]
14. 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Satoh M; Satoh A
J Pharm Pharm Sci; 2009 Feb; 11(2):118s-130s. PubMed ID: 19203474
[TBL] [Abstract][Full Text] [Related]
15. The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling.
Zeng Z; Li Y; Jiang Z; Wang C; Li B; Jiang W
Cardiovasc Ther; 2010; 28(1):23-9. PubMed ID: 20074256
[TBL] [Abstract][Full Text] [Related]
16. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.
Mouchaers KT; Schalij I; Versteilen AM; Hadi AM; van Nieuw Amerongen GP; van Hinsbergh VW; Postmus PE; van der Laarse WJ; Vonk-Noordegraaf A
Am J Physiol Heart Circ Physiol; 2009 Jul; 297(1):H200-7. PubMed ID: 19395550
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil for the treatment of pulmonary hypertension in pediatric patients.
Huddleston AJ; Knoderer CA; Morris JL; Ebenroth ES
Pediatr Cardiol; 2009 Oct; 30(7):871-82. PubMed ID: 19705181
[TBL] [Abstract][Full Text] [Related]
18. Enhanced protection against pulmonary hypertension with sildenafil and endothelial progenitor cell in rats.
Sun CK; Lin YC; Yuen CM; Chua S; Chang LT; Sheu JJ; Lee FY; Fu M; Leu S; Yip HK
Int J Cardiol; 2012 Dec; 162(1):45-58. PubMed ID: 21620490
[TBL] [Abstract][Full Text] [Related]
19. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart.
Andersen A; Nielsen JM; Peters CD; Schou UK; Sloth E; Nielsen-Kudsk JE
Eur J Heart Fail; 2008 Dec; 10(12):1158-65. PubMed ID: 19004667
[TBL] [Abstract][Full Text] [Related]
20. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Yilmaz H; Butrous G; Ermert L; Ermert M; Weissmann N; Rose F; Guenther A; Walmrath D; Seeger W; Grimminger F
Am J Respir Crit Care Med; 2004 Jan; 169(1):39-45. PubMed ID: 12958054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
